AZD3241 300 mg BID ( DrugBank: - )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
6	パーキンソン病	1

6. パーキンソン病

---

臨床試験数 : 2,307 /  薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01603069 (ClinicalTrials.gov)	October 2012	14/5/2012	A Study to Assess Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's Disease	A Phase IIa, 12 Week, Multicentre, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's Disease	Parkinson's Disease	Drug: AZD3241 300 mg BID;Drug: AZD3241 600 mg BID;Drug: Placebo	AstraZeneca	NULL	Completed	30 Years	80 Years	Both	51	Phase 2	United States